|
Estimated real time
19:24:18 11/12/2024 |
It varies. 5j. |
Varies. 1 Jan. |
||
| 7,845 USD |
-1,07 % | +7,44 % | +31,47 % | |
| BioCryst Pharmaceuticals drug for hereditary angioedema receives recommendation from Irish regulator |
18/11 |
MT |
| BioCryst Pharmaceuticals, Inc. Lance ORLADEYO® (berotralstat) in Ireland |
18/11 |
CI |
| BioCryst Pharmaceuticals narrows third-quarter loss, increases revenue, issues 2024 sales forecast |
04/11 |
MT |
| BioCryst Pharmaceuticals, Inc., Q3 2024 Earnings Call, Nov 04, 2024 |
04/11 |
|
| BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for Full Year 2024, Second Half 2025 and Full Year 2026 |
04/11 |
CI |
| BioCryst Pharmaceuticals, Inc. Announces Results for the Third Quarter and Nine Months Ending September 30, 2024 |
04/11 |
CI |
| BioCryst Pharmaceuticals Orladeyo Study Shows Reduced Hospitalizations in Patients With Hereditary Angioneurotic Edema |
14/10 |
MT |
| BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome |
02/10 |
CI |
| BioCryst wins 5-year US influenza contract worth $69 million |
30/09 |
MT |
| U.S. Government Awards BioCryst Pharmaceuticals, Inc. $69 Million Contract for RAPIVAB®? (injectable peramivir) for the strategic national stock |
30/09 |
CI |
| BioCryst Pharmaceuticals completes negotiations with Canadian pricing agency for Orladeyo |
17/09 |
MT |
| BioCryst Pharmaceuticals, Inc. announces that negotiations with the Pan-Canadian Pharmaceutical Alliance (PCPA) for once-daily oral Prorladeyo® (Berotralstat) have been successfully concluded |
17/09 |
CI |
| Biocryst Pharmaceuticals, Inc. appoints Donald Fong as chief medical officer |
05/09 |
CI |
| BioCryst Pharmaceuticals, Inc., Q2 2024 Earnings Call, Aug 05, 2024 |
05/08 |
|
| BioCryst Pharmaceuticals narrows Q2 adjusted loss and increases revenue |
05/08 |
MT |
| BioCryst Pharmaceuticals, Inc. Announces Results for the Second Quarter and Six Years Ended June 30, 2024 |
05/08 |
CI |
| BioCryst Pharmaceuticals, Inc. Revises Full Year 2024 Revenue Guidance |
05/08 |
CI |
| BioCryst Pharmaceuticals announces that Orladeyo is approved in Peru |
09/07 |
MT |
| Island Pharmaceuticals acquires clinical-stage antiviral molecule |
03/07 |
MT |
| BioCryst Pharmaceuticals Says Drug Shows Signs of Reducing Seizures in Patients With Hereditary Angioedema |
03/06 |
MT |
| BioCryst Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM |
15/05 |
|
| Sector Update: Healthcare stocks advance late Wednesday afternoon |
15/05 |
MT |
| BioCryst Pharmaceuticals shares rise 20% following disclosure of stock purchases by top executives |
15/05 |
MT |
| BioCryst Announces Orladeyo Approved in Mexico |
13/05 |
MT |
| BioCryst Pharmaceuticals, Inc. announces that the Federal Commission for Protection against Health Risks in Mexico approves ORLADEYO once daily |
13/05 |
CI |
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people with complement-mediated and other rare diseases. The company leverages its design expertise to develop first-in-class oral small molecule and protein therapeutics that target difficult-to-treat diseases. Its marketed products include ORLADEYO, administered orally once daily, for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection) and early-stage discovery programs. BCX10013 is a potent and specific factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza in patients six months of age and older.
More information about the company
Purchase
Average recommendation
ACHETER
Last Closing Course
7,930USD
Average course objective
14,82USD
Gap / Average Objective
+86,86 %
Consensus
Quarterly turnover – Surprise rate
Related News :